Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2013 Sep;29(7):612-8.
doi: 10.1089/jop.2013.0009. Epub 2013 Jun 4.

Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes

Jeeyun Ahn  1 , Hyuncheol Kim, Se Joon Woo, Ji Hyun Park, Sunyoung Park, Duck Jin Hwang, Kyu Hyung Park
Affiliations
Comparative Study

Pharmacokinetics of intravitreally injected bevacizumab in vitrectomized eyes

Jeeyun Ahn et al. J Ocul Pharmacol Ther. 2013 Sep.

Abstract

Purpose: To compare the pharmacokinetics (PKs) of intravitreally injected bevacizumab in vitrectomized versus nonvitrectomized control rabbit eyes.

Methods: Twenty-five-gauge pars plana vitrectomy without lensectomy was performed in 17 right rabbit eyes (V) and 18 nonvitrectomized right rabbit eyes served as controls (C). After 1.25 mg/0.05 mL intravitreal bevacizumab (IVB) injections, eyes were enucleated at 1 h, 1, 2, 5, 14, and 30 days after the injection and immediately frozen at -80°C. Bevacizumab concentrations were determined after separation of frozen vitreous and aqueous humor (AH) compartments using indirect enzyme-linked immunosorbent assay. Bevacizumab concentration-time data were analyzed to obtain PK data.

Results: Vitreous clearance of IVB consisted of 2 phases, the first fast distribution and second slow elimination phase. Clearance of IVB was accelerated in V eyes only during the first phase and not in the second phase. The vitreous concentration percent ratios between V and C eyes were 94.7% (1 h), 70.5% (1 day), 89.2% (2 days), 94.2% (5 days), 99.2% (14 days), and 79.1% (30 days). Overall vitreous half-lives were 6.99 and 7.06 days for V and C eyes, respectively (1.6-h difference).

Conclusion: Overall IVB PKs in rabbit eyes after vitrectomy without lensectomy are not substantially different from nonvitrectomized control eyes.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Vitreous bevacizumab concentrations over time in both vitrectomized and nonvitrectomized eye following intravitreal injection (1.25 mg) in rabbit eyes. The lines represent 2-phase exponential decay equation fit to each of the 2 data sets.
FIG. 2.
FIG. 2.
Aqueous humor (AH) bevacizumab concentrations over time in both vitrectomized and nonvitrectomized eye following intravitreal injection (1.25 mg) in rabbit eyes.
FIG. 3.
FIG. 3.
The percent ratios of vitreous and AH bevacizumab concentrations calculated as the concentration in vitrectomized eyes as a percentage of the nonvitrectomized eyes.
See this image and copyright information in PMC

References

    1. Aiello L.P. Avery R.L. Arrigg P.G., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 1994;331:1480–1487. - PubMed
    1. Spilsbury K. Garrett K.L. Shen W.Y., et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am. J. Pathol. 2000;157:135–144. - PMC - PubMed
    1. Rosenfeld P.J. Brown D.M. Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 2006;355:1419–1431. - PubMed
    1. Nguyen Q.D. Brown D.M. Marcus D.M., et al. Ranibizumab for Diabetic Macular Edema: Results from 2 Phase III Randomized Trials: RISE and RIDE. Ophthalmology. 2012;119:789–801. - PubMed
    1. Campochiaro P.A. Heier J.S. Feiner L., et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010;117:1102–1112 e1. - PubMed

Publication types

LinkOut - more resources